Ilomedin

Iloprost Trometamol, the active ingredient in Ilomedin, is a prostacyclin analog presented as a solution for injection for intravenous use. It treats pulmonary arterial hypertension, peripheral arterial disease, and digital ulcers associated with systemic sclerosis. It is approved in the European Union for specialist use and is administered under medical supervision. The product complies with GMP standards and is distributed in sterile vials suitable for controlled infusion.

GNH USA supplies Ilomedin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilomedin (iloprost trometamol) is used in the management of vascular disorders characterized by vasoconstriction and platelet activation. - Pulmonary arterial hypertension: improves exercise capacity and reduces pulmonary arterial pressure. - Peripheral arterial disease: alleviates intermittent claudication and enhances limb perfusion. - Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation. - Raynaud's phenomenon secondary to systemic sclerosis: reduces frequency and severity of vasospastic attacks.

Ilomedin may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Nausea: occasional gastrointestinal upset. - Diarrhea: loose stools. - Jaw pain: discomfort in the mandibular area. - Hypotension: transient drop in blood pressure.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure decline requiring intervention. - Pulmonary edema: fluid accumulation in the lungs. - Bleeding complications: significant hemorrhage due to antiplatelet effect. - Arrhythmias: abnormal heart rhythms. - Thrombocytopenia: low platelet count. - Anaphylaxis: acute allergic reaction.

When prescribing Ilomedin, clinicians should consider several safety and handling precautions. - Monitoring blood pressure: check systolic and diastolic values before and during infusion. - Assessing bleeding risk: evaluate for concurrent anticoagulants or coagulopathies. - Renal function: adjust use in patients with severe renal impairment. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Contraindications: do not use in patients with known hypersensitivity to iloprost or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ilomedin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Combination with anticoagulants (e.g., warfarin, heparin): increased risk of bleeding. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): additive vasodilatory effect leading to hypotension.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antiplatelet effect. - Calcium channel blockers: potential additive blood pressure lowering. - Beta‑blockers: may mask tachycardia response during infusion.